icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
adprHPPaGBmjS0Cv